# Early Extubation by ECCO2R Compared to IMV in Patients with Severe Acute Exacerbation of COPD

> **NCT03584295** · NA · TERMINATED · sponsor: **Xenios AG** · enrollment: 18 (actual)

## Conditions studied

- COPD Exacerbation

## Interventions

- **DEVICE:** Extracorporeal carbon dioxide removal
- **OTHER:** Conventional Care

## Key facts

- **NCT ID:** NCT03584295
- **Lead sponsor:** Xenios AG
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-02-07
- **Primary completion:** 2024-11-01
- **Final completion:** 2024-11-25
- **Target enrollment:** 18 (ACTUAL)
- **Why stopped:** Business decision
- **Last updated:** 2025-03-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03584295

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03584295, "Early Extubation by ECCO2R Compared to IMV in Patients with Severe Acute Exacerbation of COPD". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT03584295. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*